CAMP4 Therapeutics
Update in progressCAMP (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Camp4 Therapeutics Corporation is a clinical‑stage biopharmaceutical company that discovers and develops RNA‑based therapies for genetic diseases. Its lead candidate, CMP‑001, is in a Phase 1/2 trial for urea cycle disorders, and the company is also developing CMP‑002 for SYNGAP1‑related disorders. Formerly Marauder Therapeutics, it renamed to Camp4 Therapeutics in March 2018. It was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Company score
- Sentiment
- 0.31
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.16
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!